BDIX/OrlCrl |
blood CD8 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (between 44 and 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD8-positive T cell quantity |
male |
111 days-125 days |
21 |
|
2.1 |
x 10E6 cells/ml |
0.08 |
0.36 |
fluorescence-activated cell sorting method |
0.0 |
48 |
days |
two treatments |
fluorouracil 5-FU +IL-2+ Ta1 |
|
111105 |
3196 |
BDIX/OrlCrl |
blood CD25 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD25-positive T cell quantity |
male |
111 days-125 days |
18 |
|
2267.0 |
cells/ul |
74.25 |
315.0 |
fluorescence-activated cell sorting method |
0.0 |
48 |
days |
two treatments |
fluorouracil 5-FU +IL-2 |
|
111093 |
3196 |
BDIX/OrlCrl |
post-insult time of death due to metastatic liver tumors |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
life span trait |
male |
98 days-164 days |
18 |
median |
101.3 |
d |
3.87 |
16.4 |
necropsy |
0.0 |
0 |
|
two treatments |
5-fluorouracil + interleukin-2 |
|
111144 |
3196 |
BDIX/OrlCrl |
percentage of study population developing extra-hepatic metastases during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
peritoneum integrity trait |
male |
77 days-186 days |
21 |
|
9.5 |
% |
|
|
necropsy |
0.0 |
0 |
|
two treatments |
5-fluorouracil + thymosin alpha-1 +interleukin-2 |
|
111157 |
3196 |
BDIX/OrlCrl |
ratio of survivors to total study population during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
life span trait |
male |
77 days-163 days |
18 |
|
44.0 |
% |
|
|
in vivo visual assessment |
0.0 |
100 |
days |
two treatments |
5-fluorouracil + interleukin-2 |
|
111148 |
3196 |
BDIX/OrlCrl |
ratio of survivors to total study population during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
life span trait |
male |
77 days-213 days |
21 |
|
9.5 |
% |
|
|
in vivo visual assessment |
0.0 |
150 |
days |
two treatments |
5-fluorouracil + thymosin alpha-1 +interleukin-2 |
|
111153 |
3196 |
BDIX/OrlCrl |
post-insult time of death due to metastatic liver tumors |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
life span trait |
male |
77 days-162 days |
15 |
median |
98.7 |
d |
2.17 |
8.4 |
necropsy |
0.0 |
0 |
|
one treatment |
5-fluorouracil + thymosin alpha-1 +interleukin-2 |
|
111123 |
3196 |
BDIX/OrlCrl |
percentage of study population developing extra-hepatic metastases during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
peritoneum integrity trait |
male |
77 days-146 days |
15 |
|
93.0 |
% |
|
|
necropsy |
0.0 |
0 |
|
one treatment |
interleukin-2 |
|
111135 |
3196 |
BDIX/OrlCrl |
blood CD8 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD8-positive T cell quantity |
male |
111 days-125 days |
18 |
|
1.23 |
x 10E6 cells/ml |
0.05 |
0.23 |
fluorescence-activated cell sorting method |
0.0 |
48 |
days |
two treatments |
fluorouracil 5-FU +IL-2 |
|
111103 |
3196 |
BDIX/OrlCrl |
blood CD4 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD4-positive T cell quantity |
male |
111 days-125 days |
18 |
|
2.22 |
x 1000 cells/ul |
0.06 |
0.26 |
fluorescence-activated cell sorting method |
0.0 |
48 |
days |
two treatments |
fluorouracil 5-FU +IL-2 |
|
111113 |
3196 |
BDIX/OrlCrl |
ratio of survivors to total study population during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
life span trait |
male |
77 days-163 days |
21 |
|
81.0 |
% |
|
|
in vivo visual assessment |
0.0 |
100 |
days |
two treatments |
5-fluorouracil + thymosin alpha-1 +interleukin-2 |
|
111149 |
3196 |
BDIX/OrlIco |
metastatic liver tumor area |
PRObR1 cells (2 x 10E6 cells) then sodium butyrate (20 mmol/l) (for 7 days) and interleukin-2 (45 x 10E4 IU/kg) (for 5 days) |
Cordel S, etal., Int J Cancer. 1998 Dec 9;78(6):735-9. doi: 10.1002/(sici)1097-0215(19981209)78:6<735::aid-ijc11>3.0.co;2-6. |
liver integrity trait |
male |
116 days-146 days |
3 |
median |
23.0 |
mm2 |
|
|
magnetic resonance imaging |
0.0 |
0 |
|
|
BDIX/OrlIco |
|
109118 |
3085 |
BDIX/OrlCrl |
percentage of study population developing ascites during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
peritoneum integrity trait |
male |
77 days-147 days |
14 |
|
100.0 |
% |
|
|
necropsy |
0.0 |
0 |
|
one treatment |
thymosin alpha-1 + interleukin-2 |
|
111130 |
3196 |
BDIX/OrlCrl |
blood CD25 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD25-positive T cell quantity |
male |
91 days-105 days |
21 |
|
1215.0 |
cells/ul |
87.07 |
399.0 |
fluorescence-activated cell sorting method |
0.0 |
28 |
days |
one treatment |
fluorouracil 5-FU + IL2 +Ta1 |
|
111094 |
3196 |
BDIX/OrlCrl |
blood CD8 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD8-positive T cell quantity |
male |
91 days-105 days |
21 |
|
2.0 |
x 10E6 cells/ml |
0.11 |
0.51 |
fluorescence-activated cell sorting method |
0.0 |
28 |
days |
one treatment |
fluorouracil 5-FU + IL2 +Ta1 |
|
111104 |
3196 |
BDIX/OrlCrl |
blood CD4 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD4-positive T cell quantity |
male |
91 days-105 days |
18 |
|
1.88 |
x 1000 cells/ul |
0.07 |
0.29 |
fluorescence-activated cell sorting method |
0.0 |
28 |
days |
one treatment |
fluorouracil 5-FU + IL2 |
|
111112 |
3196 |
BDIX/OrlCrl |
percentage of study population developing extra-hepatic metastases during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
peritoneum integrity trait |
male |
77 days-164 days |
18 |
|
22.0 |
% |
|
|
necropsy |
0.0 |
0 |
|
two treatments |
5-fluorouracil + interleukin-2 |
|
111156 |
3196 |
BDIX/OrlCrl |
blood CD4 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (between 44 and 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD4-positive T cell quantity |
male |
111 days-125 days |
21 |
|
4.5 |
x 1000 cells/ul |
0.23 |
1.05 |
fluorescence-activated cell sorting method |
0.0 |
48 |
days |
two treatments |
fluorouracil 5-FU +IL-2+ Ta1 |
|
111115 |
3196 |
BDIX/OrlCrl |
ratio of survivors to total study population during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
life span trait |
male |
77 days-213 days |
18 |
|
0.0 |
% |
|
|
in vivo visual assessment |
0.0 |
150 |
days |
two treatments |
5-fluorouracil + interleukin-2 |
|
111152 |
3196 |
BDIX/OrlIco |
post-insult time of death due to metastatic liver tumors |
PROb cells (2 x 10E6 cells) then sodium butyrate (20 mmol/l) (for 7 days) and interleukin-2 (45 x 10E4 IU/kg) (for 5 days) |
Cordel S, etal., Int J Cancer. 1998 Dec 9;78(6):735-9. doi: 10.1002/(sici)1097-0215(19981209)78:6<735::aid-ijc11>3.0.co;2-6. |
life span trait |
male |
126 days-190 days |
6 |
median |
66.0 |
d |
|
|
necropsy |
0.0 |
0 |
|
|
post-insult time of death due to metastatic liver tumors (CMO:0003882) |
survival |
107420 |
3085 |
BDIX/OrlCrl |
post-insult time of death due to metastatic liver tumors |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
life span trait |
male |
77 days-147 days |
14 |
median |
84.0 |
d |
3.61 |
13.5 |
necropsy |
0.0 |
0 |
|
one treatment |
thymosin alpha-1 + interleukin-2 |
|
111122 |
3196 |
BDIX/OrlCrl |
percentage of study population developing extra-hepatic metastases during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
peritoneum integrity trait |
male |
77 days-157 days |
15 |
|
53.0 |
% |
|
|
necropsy |
0.0 |
0 |
|
one treatment |
5-fluorouracil + interleukin-2 |
|
111136 |
3196 |
BDIX/OrlCrl |
percentage of study population developing extra-hepatic metastases during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
peritoneum integrity trait |
male |
77 days-162 days |
15 |
|
13.0 |
% |
|
|
necropsy |
0.0 |
0 |
|
one treatment |
5-fluorouracil + thymosin alpha-1 +interleukin-2 |
|
111139 |
3196 |
BDIX/OrlCrl |
blood CD25 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (between 44 and 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD25-positive T cell quantity |
male |
111 days-125 days |
21 |
|
3664.0 |
cells/ul |
56.74 |
260.0 |
fluorescence-activated cell sorting method |
0.0 |
48 |
days |
two treatments |
fluorouracil 5-FU +IL-2+ Ta1 |
|
111095 |
3196 |
BDIX/OrlCrl |
blood CD8 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD8-positive T cell quantity |
male |
91 days-105 days |
18 |
|
1.1 |
x 10E6 cells/ml |
0.02 |
0.09 |
fluorescence-activated cell sorting method |
0.0 |
28 |
days |
one treatment |
fluorouracil 5-FU + IL2 |
|
111102 |
3196 |
BDIX/OrlCrl |
blood CD25 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD25-positive T cell quantity |
male |
91 days-105 days |
18 |
|
987.0 |
cells/ul |
23.81 |
101.0 |
fluorescence-activated cell sorting method |
0.0 |
28 |
days |
one treatment |
fluorouracil 5-FU + IL2 |
|
111092 |
3196 |
BDIX/OrlCrl |
post-insult time of death due to metastatic liver tumors |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
life span trait |
male |
77 days-146 days |
15 |
median |
83.1 |
d |
2.32 |
9.0 |
necropsy |
0.0 |
0 |
|
one treatment |
interleukin-2 |
|
111119 |
3196 |
BDIX/OrlCrl |
post-insult time of death due to metastatic liver tumors |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
life span trait |
male |
77 days-157 days |
15 |
median |
94.0 |
d |
2.63 |
10.2 |
necropsy |
0.0 |
0 |
|
one treatment |
5-fluorouracil + interleukin-2 |
|
111120 |
3196 |
BDIX/OrlIco |
metastatic liver tumor area |
PRObR1 cells (2 x 10E6 cells) then sodium butyrate (20 mmol/l) (for 7 days) and interleukin-2 (45 x 10E4 IU/kg) (for 5 days) |
Cordel S, etal., Int J Cancer. 1998 Dec 9;78(6):735-9. doi: 10.1002/(sici)1097-0215(19981209)78:6<735::aid-ijc11>3.0.co;2-6. |
liver integrity trait |
male |
151 days-181 days |
3 |
median |
107.8 |
mm2 |
|
|
magnetic resonance imaging |
0.0 |
0 |
|
|
BDIX/OrlIco |
|
109119 |
3085 |
BDIX/OrlCrl |
percentage of study population developing ascites during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
peritoneum integrity trait |
male |
77 days-157 days |
15 |
|
53.0 |
% |
|
|
necropsy |
0.0 |
0 |
|
one treatment |
5-fluorouracil + interleukin-2 |
|
111128 |
3196 |
BDIX/OrlCrl |
percentage of study population developing ascites during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
peritoneum integrity trait |
male |
77 days-146 days |
15 |
|
100.0 |
% |
0.0 |
0.0 |
necropsy |
0.0 |
0 |
|
one treatment |
interleukin-2 |
|
111127 |
3196 |
BDIX/OrlCrl |
percentage of study population developing extra-hepatic metastases during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
peritoneum integrity trait |
male |
77 days-147 days |
14 |
|
100.0 |
% |
|
|
necropsy |
0.0 |
0 |
|
one treatment |
thymosin alpha-1 + interleukin-2 |
|
111138 |
3196 |
BDIX/OrlCrl |
post-insult time of death due to metastatic liver tumors |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
life span trait |
male |
98 days-186 days |
21 |
median |
122.6 |
d |
2.42 |
11.1 |
necropsy |
0.0 |
0 |
|
two treatments |
5-fluorouracil + thymosin alpha-1 +interleukin-2 |
|
111145 |
3196 |
BDIX/OrlCrl |
blood CD4 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD4-positive T cell quantity |
male |
91 days-105 days |
21 |
|
3.39 |
x 1000 cells/ul |
0.16 |
0.72 |
fluorescence-activated cell sorting method |
0.0 |
28 |
days |
one treatment |
fluorouracil 5-FU + IL2 +Ta1 |
|
111114 |
3196 |
BDIX/OrlCrl |
percentage of study population developing ascites during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
peritoneum integrity trait |
male |
77 days-162 days |
15 |
|
13.0 |
% |
|
|
necropsy |
0.0 |
0 |
|
one treatment |
5-fluorouracil + thymosin alpha-1 +interleukin-2 |
|
111131 |
3196 |